PA
ACH

PharVision Advisers’s Accendra Health ACH Stock Holding History

PharVision Advisers’s Portfolio ACH Stock Details ACH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-107,865
Closed -$279K – 486
2025
Q4 		$279K Buy
107,865
+84,578
+363% +$302K 0.14% 316
2025
Q3 		$112K Buy
+23,287
New +$148K 0.06% 615

Other funds holding ACH

CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's ACH Position: Q1 2026 in Review

PharVision Advisers sold out of Accendra Health (ACH) in Q1 2026, closing a stake of 107,865 shares — an estimated $279K sold.

PharVision Advisers first reported a position in ACH in Q3 2025 and held it in 2 quarters. The position peaked at $279K in Q4 2025. 142 funds tracked by Wall St. Rank hold ACH as of Q1 2026.

  • PharVision Advisers reported no remaining Accendra Health position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 107,865 Accendra Health shares in Q1 2026, an estimated $279K.
  • PharVision Advisers first reported a position in Accendra Health in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Accendra Health position peaked at $279K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Accendra Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.